Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Protagonist Therapeutics, Inc. on June 20, 2025. The record date for the meeting was April 23, 2025, with 61,957,230 shares of common stock entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on three proposals, all of which were approved or elected as follows:
- Proposal 1 (Director Election): Harold E. Selick, Ph.D., and Bryan Giraudo were elected as Class III directors.
- Harold E. Selick, Ph.D.: 44,822,907 votes For; 9,210,036 votes Withheld.
- Bryan Giraudo: 42,499,790 votes For; 11,533,153 votes Withheld.
- Proposal 2 (Executive Compensation): The advisory vote on named executive officer compensation was approved.
- 50,844,517 votes For; 2,850,473 votes Against; 337,953 Abstentions.
- Proposal 3 (Auditor Ratification): The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
- 55,480,739 votes For; 74,233 votes Against; 396,488 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the stockholder vote.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 29, 2025, for detailed descriptions of the director nominees and executive compensation rationale.
- Confirm the tenure of the newly elected directors (Harold E. Selick and Bryan Giraudo) through the 2028 Annual Meeting.
- Review the upcoming 2025 Annual Report (10-K) for the financial performance and liquidity metrics not included in this 8-K.